| scholarly article | Q13442814 |
| P2093 | author name string | Liu Zhen | |
| Xufeng Han | |||
| Fang Yong | |||
| Han Weidong | |||
| Chen Jiali | |||
| Pan Hongming | |||
| P2860 | cites work | Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer | Q33413742 |
| Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer | Q34544166 | ||
| Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 | ||
| Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor | Q38498207 | ||
| Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma? | Q38702994 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo | Q39569400 | ||
| Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors | Q39630965 | ||
| Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction | Q39991776 | ||
| Cancer statistics in China, 2015. | Q40064386 | ||
| Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 | ||
| Sorafenib in advanced hepatocellular carcinoma. | Q46208900 | ||
| Cancer statistics, 2018. | Q47191906 | ||
| Efficacy and safety of apatinib as second-line therapy for advanced gastric cancer: a single-center observational study | Q49928255 | ||
| Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial | Q87206964 | ||
| P433 | issue | 16 | |
| P921 | main subject | liver cancer | Q623031 |
| P304 | page(s) | 2773-2777 | |
| P577 | publication date | 2018-07-16 | |
| P1433 | published in | Journal of Cancer | Q6294901 |
| P1476 | title | The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study. | |
| P478 | volume | 9 |
| Q92989160 | Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study |
| Q90136508 | Evaluation of Targeted Agents for Advanced and Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis |
| Q98386015 | Targeted therapy for hepatocellular carcinoma |
| Q90427159 | The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study |
Search more.